Forty-Eighth Board Meeting

<p>The Agenda for the 48th Board Meeting (GF/B48/01 - Revision 2) is approved.</p>

<p>Erika Satterwhite from the Private Sector Constituency is designated as Rapporteur for the 48th Board Meeting.</p>

<ol> <li>The Board acknowledges that C19RM was established to support (i) COVID-19 control and containment interventions, (ii) COVID-19 risk-related mitigation measures for programs to fight HTM, and (iii) expanded reinforcement of key aspects of health systems, and recognizes that C19RM requests and awards through the end of 2021 largely focused on the acute response to the COVID-19 pandemic;</li> <li>The Board acknowledges that the pandemic is evolving, and that recipient priorities are correspondingly shifting towards longer-term investments in health systems’ infrastructure and capacities for pandemic preparedness and response;</li> <li>To facilitate careful planning of such investments, including alignment with potential funding requests for the Seventh Replenishment grant cycle, the Board approves that C19RM funds may be awarded through 30 June 2023, with opportunity for subsequent C19RM portfolio optimization awards;</li> <li>To enable maximization of impact from investments in resilient and sustainable systems for health, the Board approves that any C19RM funds may be implemented through 31 December 2025 and will finance interventions across the Sixth and Seventh Replenishment periods – acknowledging that the Secretariat will continue to ensure rapid deployment of funds and quality implementation notwithstanding this deadline;</li> <li>The Board approves that C19RM funding requests will continue to be developed through appropriate, multi-sectoral consultation and fully inclusive decision-making, which must engage communities and civil society, and which must ensure coordination with the national COVID-19 response coordinating body or provide other evidence of alignment with the national approach to COVID-19 response in the absence of such a coordinating body;</li> <li>The Board approves that the Secretariat may use up to 4.5% of C19RM funds, representing an increase from the prior ceiling of 3%, to cover additional management and operating costs related to extension of C19RM; and</li> <li>The Board agrees that all other parameters of C19RM under GF/B46/EDP06 remain unchanged.</li> </ol>

<ol> <li>Based on the recommendation of the Audit and Finance Committee (AFC), as presented in GF/B48/03A – Revision 1, the Board approves US$ 12.903 billion as sources of funds for allocation for the 2023-2025 allocation period. The total amount of sources of funds for allocation comprises, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04: <ol type="i"> <li>US$ 13.678 billion, derived from the announced replenishment results for the Seventh Replenishment, net of adjustments;</li> <li>US$ 0.250 billion of forecasted unutilized funds from the 2020-2022 allocation period; and</li> <li>a deduction of US$ 1.025 billion of forecasted aggregate operating expenses for the 2023-2025 allocation period.</li> </ol> </li> <li>Based on the recommendation of the Secretariat to supplement the recommendation of the Strategy Committee, as presented in GF/B48/03A – Revision 1, the Board approves the use of an additional US$ 0.200 billion for catalytic investments for the 2023-2025 allocation period, bringing the total amount, from sources of funds for allocation, for catalytic investments for the 2023-2025 allocation period to US$ 0.400 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B48/03A- Revision 1, and based on the recommendation of the Secretariat, the Board approves updating the delegated authority to the Secretariat established in paragraph 7 of GF/B47/DP06 so that the Secretariat may increase the amount of funding available for the Emergency Fund by up to an additional US$ 0.020 billion, using funding approved as available by the AFC for portfolio optimization.</li> <li>Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2023-2025 allocation period, the Board requests that the Secretariat include an additional US$ 0.625 billion in the amount used to determine country allocations pursuant to the allocation methodology for the 2023-2025 allocation period in accordance with decision point GF/B47/DP05 (Allocation Methodology).</li> <li>Accordingly, the Board approves that the amount of sources of funds for country allocations for the 2023-2025 allocation period is US$ 12.503 billion, to which US$ 0.625 billion will be added prior to determining the country allocation, for a total of US$ 13.128 billion, to be used in accordance with the Allocation Methodology and decision point GF/B47/DP05.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee (AFC), and the recommendation of the Secretariat to supplement the AFC’s recommendation, the Board approves the following:</p> <ol type="i"> <li>the 2023 Work Plan and Budget Narrative, as set forth in GF/B48/02A – Revision 1; and</li> <li>the 2023 Operating Expenses Budget in the amount of US$ 340 million (comprising (i) PART A Secretariat Operating Expenses of US$ 272 million, which includes US$ 16.5 million for the Office of the Inspector General’s 2023 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 68 million), as set forth in GF/B48/02A – Revision 1.</li> </ol>

<p>The Board acknowledges and appreciates the extensive work across the partnership to incorporate past lessons into development of an improved holistic approach to Monitoring and Evaluation (M&amp;E) for the new Strategy. The Board notes the recommendations of the Strategy Committee (SC) and Audit and Finance Committee (AFC), as set forth in GF/B48/04 and:</p> <ol type="i"> <li>Endorses the components of the M&amp;E Framework as described in GF/B48/04 Annex 1;</li> <li>Approves the KPI Framework (including each Key Performance Indicator), as set forth in GF/B48/04 Annex 2;</li> <li>Approves the topics for the Multi-Year Evaluation Calendar 2023-2028 as set forth in GF/B48/04 Annex 3; and</li> <li>Delegates authority to the SC to approve changes to the Multi-Year Evaluation Calendar in 2023, following a request by the Chief Evaluation and Learning Officer and advice from the Independent Evaluation Panel.</li> </ol>

<p>The Board:</p> <ol> <li>recalls its approval of a pilot for procurement of health and non-health products via wambo.org for eligible buyers using domestic and other non-Global Fund sources of funding as detailed in GF/B37/DP09 and GF/B42/DP05; and its request that the Secretariat include the results of an evaluation of the pilot in the development of a strategy for future advancement of wambo.org to be presented for Board approval no later than November 2022;</li> <li>notes the Technical Evaluation Reference Group (“TERG”) evaluation findings and recommendations concerning the pilot discussed at the 18th meeting of the Strategy Committee; and</li> <li>understands that the Secretariat will explore appropriate solutions for the challenges raised by the TERG evaluation and continue to facilitate access to products through wambo.org, while in parallel working to strengthen the capacities of regional and national procurement channels to ensure value for money and options for access to quality-assured heath products for countries.</li> </ol> <p>Therefore, based on the Strategy Committee’s recommendation and in support of the proposed approach for non-Global Fund financed procurements, as detailed in GF/B48/05, the Board approves:</p> <ol> <li>The Secretariat’s continued operationalization of the current scope of non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for products and services as they become available on wambo.org;</li> <li>Removing any cap related to non-Global Fund-financed orders; and</li> <li>Incorporating reporting on the non-Global Fund-financed procurement mechanism into annual updates to the Board on NextGen Market Shaping implementation</li> </ol>

<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Approves the revisions to the Honorarium Framework of the Global Fund set out in Annex 4 to GF/B48/ER01; and,</li> <li>Notes that the revisions regarding the leadership of the Board’s Standing Committees (“Committee Leaderships”) shall enter into force upon the approval of this decision point, and that Committee Leaderships shall be eligible to receive, from May 2022, the honoraria provided for in the Honorarium Framework as revised pursuant to this decision; and,</li> <li>Notes that the revisions regarding the Independent Evaluation Panel shall enter into force on 1 January 2023.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B48/ER02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER02(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the appointment of:</p> <ol> <li>Anne-Claire AMPROU, representing the France Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Ina von Frantzius and Louis da Gama, to serve in their personal capacity as voting members of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of their successors.</li> </ol>

<p>The Report of the 48th Board Meeting was approved by the Board of the Global Fund via electronic vote on 24th March 2023 (GF/B48/EDP06).</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER08(“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 2 of GF/B48/ER08(“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B48/ER08 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER09 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants, in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board appoints Lady Roslyn Morauta as Chair and Ms. Bience Gawanas as Vice-Chair of the Board to each serve three-year terms, or until the appointment of their respective successors, starting from the adjournment of the 49th Board Meeting on 11 May 2023.</p>

<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of Viet Nam to host the Global Fund’s 49th Board Meeting on 10-11 May 2023; and</li> <li>Acknowledges the recommendation set forth in GF/B48/ER04.</li> <li>Requests the Global Fund Secretariat to engage with the Government of Viet Nam to agree on any necessary arrangements relating to hosting the Board Meeting in Viet Nam, and invites the Government of Viet Nam to consider conferring privileges and immunities to the Global Fund.</li> </ol> </li> <li>Accordingly, the Board agrees to convene the 49th Board Meeting in Hanoi, Viet Nam.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B48/ER11 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B48/DP03, which approves C19RM funds to be awarded through 30 June 2023, with opportunity for subsequent C19RM Portfolio Optimization awards;</li> <li>Approves the additional funding recommended for each country listed in Table 1 of GF/B48/ER13 (“Table 1”); and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2022 Annual Financial Report, including the 2022 Annual Financial Statements which have been audited by KPMG SA, as set forth in Annex 1 to GF/B48/ER12.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2022 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B48/ER12.</p>